All In Biotech

Drug Trial Radar · NCT07940803

A Research Study of a New Medicine NNC0662-3168 for Weight Management and Type 2 Diabetes

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0662-3168 in Participants With Overweight or Obesity and Proof of Concept in Participants With Type 2 Diabetes.

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Nov 13, 2026

Primary completion

Mar 25, 2028

Study completion Mar 25, 2028

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn more about NNC0662-3168 as a potential treatment for people living with overweight or obesity and/or type 2 diabetes(T2D). The study will investigate its safety, tolerability and its effects in the body. The study will be conducted in four parts. Part A: Single Ascending Dose, Part B: Multiple Ascending Dose: Part C: Dose-finding in Weight Management. Part D: T2D proof-of-concept.

Conditions

  • Overweight
  • Obesity
  • Type 2 Diabetes Mellitus

Interventions

  • NNC0662-3168 (Test product-A)Drug

    NNC0662-3168 is administered subcutaneously.

  • Placebo matched to NNC0662-3168 (Test product-A)Drug

    Placebo is administered subcutaneously.

  • Active Comparator (Product-B)Drug

    Active Comparator is administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of treatment-emergent adverse events (TEAEs)Time frame: From dosing on day 1 upto 29 days
  2. Part B: Number of treatment-emergent adverse events (TEAEs)Time frame: From dosing at week 0 up to 39 weeks
  3. Part C: Change in body weightTime frame: From baseline (week 0) to week 36
  4. Part D: Change in glycated haemoglobin (HbA1c)Time frame: From baseline (week 0) to week 28

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Celerion, Phoenix

    Tempe, Arizona

  • Celerion, Lincoln

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.